IGM Biosciences halts development of auto-immune treatments, shares plummet

Investing.com -- IGM Biosciences (NASDAQ:IGMS ), a biotechnology company, has seen a sharp 67% drop in its stock value on Friday following the suspension of two of its treatments for autoimmune diseases.

The halted development projects include Imvotamab and IGM-2644.

The company is known for its research and development in the biotech field, specifically focusing on treatments for autoimmune diseases.

“Interim data from the Phase 1b studies of imvotamab in rheumatoid arthritis and systemic lupus erythematosus show that the depth and consistency of B cell depletion is insufficient to meet our high bar for success,” Mary Harler, Chief Executive Officer of IGM Biosciences said in a press release on Thursday.

The comapny decided to discontinue further development of imvotamab due to these findings.

"Concurrent with discontinuation of the imvotamab program, IGM-2644 is also being terminated due to strategic considerations,” Harler added.

The sudden halt in the progression of these two treatments has led to a significant decrease in the company's share value.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com

Последние публикации
Oklo target nearly doubled at Wedbush on AI-driven demand for nuclear energy
24.01.2025 - 18:00
Crypto markets lose steam after Trump's first policy move
24.01.2025 - 18:00
Combination of Google's TPU-DeepMind units may be worth $700 bn - DA Davidson
24.01.2025 - 18:00
British American Tobacco, Altria shares rise after menthol ban proposal dropped
24.01.2025 - 18:00
Morocco stocks higher at close of trade; Moroccan All Shares up 0.34%
24.01.2025 - 18:00
Commerzbank says no talks with UniCredit until specific proposal made
24.01.2025 - 18:00
Venture Global aims for $64 billion valuation at debut in test for energy IPOs
24.01.2025 - 18:00
Intuitive Machines stock surges on NASA contract award
24.01.2025 - 18:00
International Paper's $7.2 billion acquisition of DS Smith gets EU approval
24.01.2025 - 18:00
Short-term stock optimism soars among retail investors, AAII survey shows
24.01.2025 - 18:00
Venture Global shares likely to open up to 6% above IPO price
24.01.2025 - 18:00
Intuitive Surgical, American Express Stir Friday's Market Cap Stock Movers
24.01.2025 - 18:00
BMW joins Chinese EV makers in filing EU court challenge to tariffs
24.01.2025 - 18:00
Turkey stocks lower at close of trade; BIST 100 down 0.08%
24.01.2025 - 18:00
Diageo stock jumps on possible Guinness sale
24.01.2025 - 18:00

© Analytic DC. All Rights Reserved.

new
Анализ рынка Как повлият завтра отчет NFP на курс доллара США?